| Prev Close | 22.37 |
| Open | 22.72 |
| Day Low/High | 22.30 / 23.02 |
| 52 Wk Low/High | 11.98 / 22.55 |
| Volume | 1.34M |
Alkermes Plc (ALKS)
22.86
0.49
2.20
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 159.15B |
| Market Cap | 3.56B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Alkermes Is Getting Ready for a Rally
ALKS's choppy trading period may be coming to a close.
Alkermes Jumps on License Deal With Biogen -- Biotech Movers
Alkermes and Biogen have inked a pact to develop and commercialize ALKS 8700, which is in Phase 3 development for treating relapsing forms of multiple sclerosis.
Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports
A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.
Could These 9 Drugs Gain FDA Approval in the Age of Trump?
Nine biotech and drug companies want FDA approval, but need changed standards to get it.
The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
The firms all have drugs they want the feds to bend the rules to approve.
Bullish and Bearish Reversals for the Week
Materials, financials, cyclicals and health care names tilt the scale to the bullish side.
Cramer: M&A Is Just the Beginning of Today's Story
Ask not for whom the register rings, and it better not ring for thee.
An Uninspiring Start
So much for the market opening flat. Futures took a tumble for the worse in the last hour before the open and equities are down across the board in early trading. The dollar is up nicely and oil is slightly down as we commence the last trading day o...
Want a Dash for Trash? Why Not Look at Alkermes
Sometimes, buying low can work as a balance, almost a strange sort of diversification.
Stalking a Speculative Trade in Alkermes
The longer-term weekly chart is ugly, but optimistic in the near-term.
Should Acadia, Alkermes Shares be at the Top of Your Buy List?
Shares of Acadia Pharmaceuticals (ACAD) popped over 25% this week after an FDA panel voted in favor of approving its drug for Parkinson's disease psychosis.
Alkermes, Tesla & Disney Shares Set for Strong 2016 Performances
Shares of Alkermes (ALKS) were up 30 percent in 2015 and the biotech company’s strong pipeline for psychiatric drugs bodes well for another strong year in the market.
Weak Chinese Demand Is Already Priced Into Caterpillar's Stock (Plus: MYL, T, DRG, URBN)
CAT not going down on bearish news gets us closer to a bottom and buy recommendation.
Charts of the Week: Boston Scientific, Alkermes, Snap-on, Stanley Black & Decker
These four names stood out to me from a weekly perspective.
The Biotechs Are Feeling Better
Sector could regain its leadership role.
A 'Who's Who' of Tax-Domicile Targets
Each of these 'real' American firms is now a buyout candidate because of the ridiculous U.S. tax code.
